Smoking and immunomodulators do not influence the response or duration of response to infliximab in Chrohn's disease

Inflammatory Bowel Diseases

Volumn 10, Issue 4, 2004, Pages 346-351

  Fefferman, David S ^a   Lodhavia, Parag J ^b   Alsahli, Mazen ^a   Falchuk, Kenneth R ^a   Peppercorn, Mark A ^a   Shah, Samir A ^b   Farrel, Richard J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Crohn's disease; Immunomodulators; Infliximab; Predictors of response; Smoking

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; AGE; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE DURATION; DRUG INFUSION; DRUG RESPONSE; FEMALE; FOLLOW UP; GENDER; HUMAN; INTESTINE FISTULA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONSET AGE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; FISTULA; GASTROINTESTINAL AGENTS; HUMANS; MALE; PROGNOSIS; RISK FACTORS; SMOKING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3543074116     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200407000-00004     Document Type: Article

References (27)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337:1029-1035.
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
3. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000;95:3490-3497.
4. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469-3477.
5. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722-729.
6. Sample C, Bailey RJ, Todoruk D, et al. Clinical experience with infliximab for Crohn's disease: The first 100 patients in Edmonton. Alberta. Can J Gastroenterol. 2002;16:165-170.
7. Hanauer SB, Feagan BR, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial. Lancet. 2002;359: 1541-1549.
8. Sands B, van Deventer SJ, Bernstein C, et al. Long-term treatment of fistulizing Crohn's disease: response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology. 2002;122:A81.
9. Remicade. (infliximab). Centocor Inc., 2000.
10. Arseneau KO, Cohn SM, Cominelli F, et al. Cost-utility of initial medical management for Crohn's perianal fistulae. Gastroenterology. 2001;120: 1640-1656.
11. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49-57.
12. Rice MD, Arseneau KO, Bickstone SJ, et al. Inpatient and outpatient costs of care for inflammatory bowel disease in the year 2000. Gastroenterology. 2001;120:A12.
13. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002;35:151-156.
14. Mascheretti S, Hampe J, Kuhbacher T, et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J. 2002;2: 127-136.
15. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn's disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37:818-824.
16. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology. 2002; 123:106-111.
17. Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics. 2002;12:509-515.
18. Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001;120:1347-1355.
19. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol. 2002;97:1458-1462.
20. Shetty A, Forbes A. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. Am J Pharmacogenomics. 2002;2:215-221.
21. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002;97: 2357-2363.
22. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002;123: 707-13.
23. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology. 1996;110: 424-431.
24. Mayer L, Han C, Bala M, et al. Three dose induction regimen of infliximab is superior to a single dose in patients with Crohn's disease. Am J Gastroenterol. 2001;96:S303.
25. Kinney TP, Rawlins M, Kozarek R, et al. Coadministration of immunomodulators agents alters response to infliximab in Crohn's disease. Am J Gastroenterol. 2001;96:A942.
26. Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
27. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917-924.